首页/数据集/Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer. Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer

Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer. Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer

NIAID Data Ecosystem2026-05-01 收录

前列腺癌药物研究

CDK9抑制剂抗肿瘤活性

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1074417 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

应用场景：

创建时间：

2024-02-07

前列腺癌药物研究

细胞周期基因

Siomycin A treatment in prostate cancer cell lines resulted in a concurrent inhibition of specific cell cycle genes and strongly impaired cell viability. Overall design: Illumina microarray experiment

NIAID Data Ecosystem80

Discovery of 2‑(1-(3-Chloro-4-cyanophenyl)‑1 H ‑pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor

AR拮抗剂设计

前列腺癌药物研究

The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of

NIAID Data Ecosystem50

Third Generation Quinoline-3-Carboxamide Transcriptional Disrupter of HDAC4, HIF-1a, and MEF-2 Signaling for Metastatic Castration-Resistant Prostate Cancer

前列腺癌药物研究

癌细胞转录组

The quinoline-3-carboxamide, Tasquinimod, is orally active as a maintenance therapy with an on-target mechanism-of-action via allosteric binding to HDAC4. This prevents formation of the HDAC4/NCoR1/HD

NIAID Data Ecosystem20

RNA oligonucleotide sequences.

前列腺癌药物研究

转录组研究

The increasing incidence of prostate cancer (PCa) indicates an urgent need for the development of new effective drug therapy. There are limited options to treat the PCa, this study tried to determine

NIAID Data Ecosystem50

Additional file 1: of JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells

前列腺癌药物研究

药物作用机制

IC50 results. The IC50 of LNCaP and C4-2 cell lines that treated by JS-K. (XLSX 10 kb)

Figshare2017-05-27 更新40